Gilead's Biktarvy Approval Heightens HIV Competition With ViiV
Executive Summary
Gilead hopes Biktarvy will enable it to win market share away from ViiV's dolutegravir-containing regimens, but ViiV filed a patent infringement case within hours of the US FDA approval of Gilead's new combo.
You may also be interested in...
From Treatment To Prevention To A Cure: An Interview With Gilead’s HIV R&D Leaders
Gilead execs Jared Baeten and Tomas Cihlar talk to Scrip about how the company, still the leader in HIV, is working toward less-frequent dosing, providing PrEP for broader populations and maybe finding a cure for HIV infection.
Magrolimab Falls Off The Fast Track As Gilead Reveals New Clinical Holds
The company said in its fourth quarter earnings report that it would not seek accelerated approval for the drug, while it also settled an HIV drug-related intellectual property lawsuit with GSK/ViiV.
Biktarvy, PrEP Continue Driving Gilead’s HIV Dominance
HIV remains the main growth franchise for Gilead, despite an anticipated first quarter revenue downturn due to inventory and payer mix. Biktarvy’s launch and growth in PrEP business provide multiple drivers for the franchise.